Arvinas, Inc. (ARVN)
6.76
-0.06
(-0.88%)
USD |
NASDAQ |
Nov 16, 16:00
6.76
0.00 (0.00%)
After-Hours: 20:00
Arvinas Enterprise Value : -104.09M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | -104.09M |
| November 12, 2026 | -100.82M |
| November 11, 2026 | -98.20M |
| November 10, 2026 | -97.54M |
| November 09, 2026 | -108.02M |
| November 06, 2026 | -130.94M |
| November 05, 2026 | -121.78M |
| November 04, 2026 | -64.79M |
| November 03, 2026 | -86.40M |
| November 02, 2026 | -58.24M |
| October 30, 2026 | -35.97M |
| October 29, 2026 | -33.35M |
| October 28, 2026 | -53.00M |
| October 27, 2026 | -62.82M |
| October 26, 2026 | -72.00M |
| October 23, 2026 | -72.65M |
| October 22, 2026 | -45.14M |
| October 21, 2026 | -55.95M |
| October 20, 2026 | -49.07M |
| October 19, 2026 | -75.27M |
| October 16, 2026 | -94.26M |
| October 15, 2026 | -81.82M |
| October 14, 2026 | -104.09M |
| October 13, 2026 | -102.78M |
| October 12, 2026 | -62.82M |
| Date | Value |
|---|---|
| October 09, 2026 | -50.38M |
| October 08, 2026 | -58.90M |
| October 07, 2026 | -62.82M |
| October 06, 2026 | -72.00M |
| October 05, 2026 | -62.17M |
| October 02, 2026 | -65.44M |
| October 01, 2026 | -64.14M |
| September 30, 2026 | -44.16M |
| September 29, 2026 | -69.95M |
| September 28, 2026 | -69.30M |
| September 25, 2026 | -64.07M |
| September 24, 2026 | -51.01M |
| September 23, 2026 | -48.40M |
| September 22, 2026 | -3.997M |
| September 21, 2026 | -17.71M |
| September 18, 2026 | -18.36M |
| September 17, 2026 | -17.06M |
| September 16, 2026 | -26.85M |
| September 15, 2026 | -20.32M |
| September 14, 2026 | -11.18M |
| September 11, 2026 | -7.915M |
| September 10, 2026 | 9.063M |
| September 09, 2026 | 12.33M |
| September 08, 2026 | 33.22M |
| September 04, 2026 | 53.47M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 12.61M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Fulcrum Therapeutics, Inc. | -12.85M |
| Definium Therapeutics, Inc. | 3.381B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.90M |
| Revenue (Quarterly) | 0.50M |
| Total Expenses (Quarterly) | 54.40M |
| EPS Diluted (Quarterly) | -0.8242 |
| Gross Profit Margin (Quarterly) | -140.0% |
| Profit Margin (Quarterly) | -10.78K% |
| Earnings Yield | -2.73% |
| Normalized Earnings Yield | -1.833 |